Mizuho Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has reiterated a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained the price target of $82.
December 08, 2023 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst reaffirms Buy rating and $82 price target for CRISPR Therapeutics.
The reiteration of a Buy rating by a reputable analyst like Salim Syed from Mizuho is likely to instill confidence in investors and could positively influence CRISPR Therapeutics' stock price in the short term. The maintained price target of $82 suggests a potential upside from the current trading price, assuming the market aligns with the analyst's valuation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100